Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (MDNA)
NASDAQ:MDNA
Holding MDNA?
Track your performance easily
MDNA Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Medicenna Therapeutics Corp News
MDNA FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Currently, no data Available
What is Medicenna Therapeutics Corp’s market cap?
Currently, no data Available
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Currently, no data Available
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicenna Therapeutics Corp have?
Currently, no data Available
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in MDNA
---
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
---
MDNA Stock 12 Month Forecast
Average Price Target
―Medicenna Therapeutics Corp
―
Resverlogix
―
Reliq Health Technologies
―
BriaCell Therapeutics
―
Sirona Biochem
―
Best Analysts Covering MDNA
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-60.72%
reiterated a buy rating a year ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -60.72% per trade.
---